EAST EastPharma

NOTIFICATION OF CHANGE IN SHAREHOLDING

NOTIFICATION OF CHANGE IN SHAREHOLDING

11 September 2018

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (“MAR”). Upon publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. The Company confirms that it currently has no unpublished price sensitive information.

EASTPHARMA LTD

("the Company")

NOTIFICATION OF CHANGE IN SHAREHOLDING

In conformity with the disclosure and transparency rules of the United Kingdom Listing Authority (“UKLA”) (“DTR”) and MAR, the Company hereby notifies the market of the following:

The Company received notice that on 6 September 2018, Investimentos Corp acquired 5,524,283 ordinary shares in the capital of the Company from D.E. Shaw Laminar Portfolios, L.L.C. (“DE Shaw”) (representing 8.2% of the issued share capital of the Company) (the “Acquisition”).

Investimentos Corp is an investment company incorporated in the Bahamas, established by Mr. Philipp Haas (the Chairman and CEO of the Company).

Following the Acquisition, Mr. Haas holds 0.9% of the issued share capital of the Company and subject to trustee discretion may beneficially hold a further interest of up to 8.2 % of the issued share capital of the Company.

The Company

EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit .

THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN JURISDICTIONS OTHER THAN THE UNITED KINGDOM MAY BE RESTRICTED BY LAW AND THEREFORE ANY PERSONS WHO ARE SUBJECT TO THE LAWS OF ANY JURISDICTION OTHER THAN THE UNITED KINGDOM SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY APPLICABLE REQUIREMENTS. THIS ANNOUNCEMENT HAS BEEN PREPARED FOR THE PURPOSES OF COMPLYING WITH ENGLISH LAW AND THE INFORMATION DISCLOSED MAY NOT BE THE SAME AS THAT WHICH WOULD HAVE BEEN DISCLOSED IF THIS ANNOUNCEMENT HAD BEEN PREPARED IN ACCORDANCE WITH THE LAWS AND REGULATIONS OF ANY JURISDICTION OUTSIDE OF ENGLAND.

EN
11/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EastPharma

 PRESS RELEASE

Statement re Cancellation

Statement re Cancellation EASTPHARMA LTD (“the Company” or “Eastpharma”) EASTPHARMA’S DELISTING OF ITS GDRS Further to the Company's announcement of 2 May 2019, Eastpharma announces that the cancellation of the the standard listing of its Global Depositary Receipts (“GDRs”) on the Official List and the London Stock Exchange ("LSE") and the cancellation of the admission of the GDRs to trading on the main market of the LSE (the "LSE Delisting") is now effective as of 8.00 a.m.(London time) today, 1 August 2019.  As a result of the above, the relationship agreement entered into at the time...

Farida Salama ... (+3)
  • Farida Salama
  • Mariam Wael
  • Mohamed Hamza

Egypt (Pharos): Pharos Investor Conference: Meeting Minutes – Non-Fo...

The Egyptian middle class is c30mn with a household income between EGP7,000-60,000. In this report, we review CIRA, EAST, MTIE and ORWE.

 PRESS RELEASE

Annual General Meeting of EastPharma Ltd.

Annual General Meeting of EastPharma Ltd. EASTPHARMA LTD. London, 29 May 2019 - EastPharma (EAST LI), today announces that following todays's Annual General Meeting of EastPharma Ltd, the Board of EastPharma Ltd is pleased to announce that the resolutions for ordinary general assembly meeting proposed were duly passed by shareholders and all the information can be reached through EastPharma Ltd - a company active in manufacturing and marketing of pharmaceutical products in Turkey and in other regional markets; for further information please visit  Attachment ...

Mohamed Hamza
  • Mohamed Hamza

Egypt (Pharos): Eastern Tobacco Q3 18/19 – topline weakens sequentia...

EAST 3Q18/19 revenue increased by 4% YoY but fell 9% QoQ. Since the last price hike was implemented in July 2018, we believe the sequential drop in revenues is the result of slow volume growth, possibly due to weak purchasing power, or lower exports as a result of a stronger EGP/USD. The annual increase in revenues was mostly price-driven, where ASP went up by c.15% in July 2018.

 PRESS RELEASE

Annual General Meeting of EastPharma Ltd.

Annual General Meeting of EastPharma Ltd. EASTPHARMA LTD. London, 02 May 2019 - EastPharma (EAST LI), today announces that the Annual General Meeting is to be held at 10.00 am on 29 May 2019 at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. The formal notice of the Meeting and agenda for the Meeting are provided below and audited financial statements of the Company for the year ended 31 December 2018 is available for viewing on the company's website . EastPharma Ltd - a company active in the manufacturing and marketing of pharmaceutical products in Turkey and in o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch